Maui Derm Conferences

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

In this Q&A, Hilary Baldwin, MD, discusses common misperceptions, the current pipeline, and how she separates rosacea from acne.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, discussed early clues for scarring alopecia, pipeline JAK inhibitors, and setting patient expectations.

Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

At Maui Derm Summer 2026, Hilary Baldwin, MD, used a single theoretical patient to illustrate how rosacea subtypes evolve and how treatment should follow suit.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

Frieden discusses somatic mutations driving vascular malformations and how repurposed cancer therapies like alpelisib and sirolimus are changing care.

Frieden shares practical tips on repurposing topical timolol and sirolimus for pediatric skin conditions.

Frieden on expanding dupilumab use in pediatric skin conditions: prurigo nodularis, EB pruriginosa, and more.

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

Dawn Eichenfield, MD, discusses off-label treatment rationale, biologics, JAK inhibitors, and care gaps in rare pediatric skin conditions.

Donna Culton, MD, PhD, explains why autoimmune blistering diseases often look nothing like the textbook and how to pursue the diagnosis anyway.

Stefan Weiss, MD, on recognizing mast cell disorders in the dermatology clinic and how avapritinib is reshaping treatment for indolent systemic mastocytosis.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Eichenfield speaks in this interview about several key takeaways drawn from her master class in pediatric dermatology at Maui Derm Hawaii.

This segment of an interview from Maui Derm Hawaii, featuring Mark Kaufmann, MD, highlights key advice on AI scribe use and billing effectiveness in dermatology practices.

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.